Why are acute ischemic stroke patients not receiving IV tPA?
暂无分享,去创建一个
Eric E. Smith | Deepak L. Bhatt | E. Peterson | L. Schwamm | J. Saver | G. Fonarow | S. Messé | M. Reeves | Maria V. Grau‐Sepulveda | P. Khatri | M. Cox | Margueritte Cox | E. Smith
[1] Eric E. Smith,et al. Patterns, Predictors, Variations, and Temporal Trends in Emergency Medical Service Hospital Prenotification for Acute Ischemic Stroke , 2012, Journal of the American Heart Association.
[2] Joseph P. Broderick,et al. Relationship of National Institutes of Health Stroke Scale to 30-Day Mortality in Medicare Beneficiaries With Acute Ischemic Stroke , 2012, Journal of the American Heart Association.
[3] Andrew N. Brown,et al. Utilization of Intravenous Tissue-Type Plasminogen Activator for Ischemic Stroke at Academic Medical Centers: The Influence of Ethnicity , 2001, Stroke.
[4] G Schlaug,et al. Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility , 2001, Neurology.
[5] Eric E. Smith,et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. , 2014, JAMA.
[6] Geoff Cohen,et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis , 2012, The Lancet.
[7] F. Veith,et al. Letter by Paraskevas et al regarding article, "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/american Stroke Association". , 2011, Stroke.
[8] L. Lisabeth,et al. Sex differences in the use of intravenous rt-PA thrombolysis treatment for acute ischemic stroke: a meta-analysis. , 2009, Stroke.
[9] M. Conaway,et al. Ninety-Day Outcome Rates of a Prospective Cohort of Consecutive Patients With Mild Ischemic Stroke , 2012, Stroke.
[10] Li Liang,et al. Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2009, Circulation.
[11] Eric E. Smith,et al. Are Quality Improvements in the Get With The Guidelines-Stroke Program Related to Better Care or Better Data Documentation? , 2011, Circulation. Cardiovascular quality and outcomes.
[12] Eric E. Smith,et al. Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): results from a national data validation audit. , 2012, American heart journal.
[13] Gordon H Guyatt,et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[14] B. Ovbiagele,et al. Sex differences in revascularization interventions after acute ischemic stroke. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[15] Jeffrey L Saver,et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. , 2009, Stroke.
[16] W. Rosamond,et al. Racial-Ethnic Disparities in Stroke Care: The American Experience A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.
[17] K. Lees,et al. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive , 2010, BMJ : British Medical Journal.
[18] Geoff Cohen,et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.
[19] 鮫島 浩,et al. Population-based study からみた神経予後不良因子の検討 , 2009 .
[20] Eric E. Smith,et al. Comparison of Performance Achievement Award Recognition With Primary Stroke Center Certification for Acute Ischemic Stroke Care , 2013, Journal of the American Heart Association.
[21] Eric E. Smith,et al. Race/Ethnicity, Quality of Care, and Outcomes in Ischemic Stroke , 2010, Circulation.
[22] K. Lee. Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2010 .
[23] M. Kaste,et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.
[24] Eric E. Smith,et al. Quality of Care in Women With Ischemic Stroke in the GWTG Program , 2009, Stroke.
[25] A. Demchuk,et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. , 2001 .
[26] Mohit Sharma,et al. The complexities of acute stroke decision-making: A survey of neurologists , 2014, Neurology.
[27] Eric E. Smith,et al. Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines–Stroke Hospitals , 2013, Circulation. Cardiovascular quality and outcomes.
[28] M. Wintermark,et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.
[29] P. Sandercock,et al. Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Patients With Mild Stroke in the Third International Stroke Trial-3: Post Hoc Analysis , 2015, Stroke.
[30] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[31] Eric E. Smith,et al. Poor Outcomes in Patients Who Do Not Receive Intravenous Tissue Plasminogen Activator Because of Mild or Improving Ischemic Stroke , 2005, Stroke.
[32] Eric E. Smith,et al. Use of Tissue-Type Plasminogen Activator Before and After Publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke , 2012, Circulation. Cardiovascular quality and outcomes.
[33] L. Schwamm,et al. Hospital treatment of patients with ischemic stroke or transient ischemic attack using the "Get With The Guidelines" program. , 2008, Archives of internal medicine.
[34] Dawn Kleindorfer,et al. Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States: A Doubling of Treatment Rates Over the Course of 5 Years , 2011, Stroke.
[35] J. Montaner,et al. The gender gap in stroke: a meta‐analysis , 2012, Acta neurologica Scandinavica.
[36] Eric E. Smith,et al. Clinical Policy: Use of intravenous tPA for the management of acute ischemic stroke in the emergency department. , 2013, Annals of emergency medicine.
[37] Eric E. Smith,et al. Predictors of Increased Intravenous Tissue Plasminogen Activator Use Among Hospitals Participating in the Massachusetts Primary Stroke Service Program , 2012, Circulation. Cardiovascular quality and outcomes.
[38] Eric E. Smith,et al. Representativeness of the Get With The Guidelines–Stroke Registry: Comparison of Patient and Hospital Characteristics Among Medicare Beneficiaries Hospitalized With Ischemic Stroke , 2012, Stroke.
[39] F. Schmidt. Meta-Analysis , 2008 .
[40] S. Johnston,et al. Why are eligible thrombolysis candidates left untreated? , 2006, American journal of preventive medicine.
[41] Joseph P Broderick,et al. Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Population-Based Study , 2004, Stroke.
[42] Atte Meretoja,et al. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months , 2013, Neurology.
[43] S. Cramer,et al. Treatment With Tissue Plasminogen Activator and Inpatient Mortality Rates for Patients With Ischemic Stroke Treated in Community Hospitals , 2001, Stroke.
[44] H. Diener,et al. Influence of Age on Outcome From Thrombolysis in Acute Stroke: A Controlled Comparison in Patients From the Virtual International Stroke Trials Archive (VISTA) , 2010, Stroke.
[45] H. Cloft,et al. Racial and ethnic disparities in the use of intravenous recombinant tissue plasminogen activator and outcomes for acute ischemic stroke. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[46] P. Sandercock,et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository , 2014 .